---
title: "Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286092727.md"
description: "London-based Mereo BioPharma Group plc (NASDAQ: MREO) revealed its financial performance for the first quarter ending March 31, 2026. The company, specializing in rare diseases, shared updates on recent corporate activities."
datetime: "2026-05-12T11:31:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286092727.md)
  - [en](https://longbridge.com/en/news/286092727.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286092727.md)
---

# Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates

London-based Mereo BioPharma Group plc (NASDAQ: MREO) revealed its financial performance for the first quarter ending March 31, 2026. The company, specializing in rare diseases, shared updates on recent corporate activities.

### Related Stocks

- [MREO.US](https://longbridge.com/en/quote/MREO.US.md)

## Related News & Research

- [Mereo BioPharma Shareholders Approve All AGM Resolutions](https://longbridge.com/en/news/286435474.md)
- [Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments | CUE Stock News](https://longbridge.com/en/news/286460513.md)
- [CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates | CRVO Stock News](https://longbridge.com/en/news/286766468.md)
- [Autonomix Medical Announces Abstract Acceptances at EuroPCR 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation | AMIX Stock News](https://longbridge.com/en/news/286772951.md)
- [Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform | XBIO Stock News](https://longbridge.com/en/news/286257227.md)